The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home

Physiogenex provides preclinical CRO services and expertise with a 15-year expertise in evaluating drugs targeting obesity/diabetes, NASH/fibrosis, diabetic nephropathy & cardiovascular complications, dyslipidemia/atherosclerosis.

See our most popular models:

ultra-fast 3-week NASH mouse model
Our unique human-like NASH hamster model validated with OCA and elafibranor
MCD mouse and CCl4 or TAA liver fibrosis models
Our original DIO rat model fed a free-choice diet
DIO mouse model for radioactive clamp experiments
Innovative and awarded diabetic nephropathy mouse and rat models
Atherosclerosis models

All our models are provided with benchmarks and validated in vivo experiments, biochemical assays and histology analysis/NAS scoring. Frozen/fixed biological samples from our models can be shipped to test your biomarkers and therapeutic target.

PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS

Our services to evaluate your drugs targeting

DIABETES

Insulin resistance OBESITY

LIVER DISEASES

NAFLD Hepatic steatosis to fibrosis

DYSLIPIDEMIA ATHEROSCLEROSIS

DIABETIC NEPHROPATHY

Animal models from basic to predictive in-house models

Experimental platform From gold-standard to innovative assays

Scientific expertise and translational vision

News, Events and Publications

87th EAS Congress (May 26-29, 2019) in Maastricht, Netherlands

3rd Annual NASH Summit (April 22-25, 2019) in Boston, Massachusetts, USA.

Keystone Symposia Immunometabolism, Metaflammation and Metabolic Disorders, (April 14-18, 2019) in Vancouver, British Columbia.

Physiogenex to present radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the WCIR 2018 in Los Angeles, CA, USA

PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS

Our services to evaluate your drugs targeting

News, Events and Publications

87th EAS Congress (May 26-29, 2019) in Maastricht, Netherlands

3rd Annual NASH Summit (April 22-25, 2019) in Boston, Massachusetts, USA.

Keystone Symposia Immunometabolism, Metaflammation and Metabolic Disorders, (April 14-18, 2019) in Vancouver, British Columbia.

The International Liver Congress – Annual EASL meeting (April 10-14, 2019), in Vienna, Austria.

Keystone Unraveling the Secrets of Kidney Disease (March 3-7, 2019), in Whistler, British Columbia, Canada.

Asian Pacific Association for the Study of the Liver Annual Convention, February 20-24, 2019 (Manila, Philippines)

Physiogenex to present at the Keystone Obesity and Adipose Tissue Biology in Banff, Alberta, Canada

Physiogenex to present at the Keystone NASH and NAFLD in Santa Fe, NM, USA

Physiogenex to present at the NASH-TAG 2019

Physiogenex to present radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the WCIR 2018 in Los Angeles, CA, USA

Physiogenex to present the effects of green coffee and green tea in DIO mice at Obesity Week 2018 in Nashville, TN, USA

Physiogenex to present its 3-week ultra-fast NASH screening mouse model at the AASLD Liver Meeting 2018

Physiogenex and its industry partners to present at the ASN Kidney Week 2018, October the 27th, 2018, San Diego, CA, USA.